Intranasal delivery of biotechnology-based therapeutics-Reference-Cited by-同舟云学术

Intranasal delivery of biotechnology-based therapeutics

Published:2022-12 Issue:12 Volume:27 Page:103371
ISSN:1359-6446
Container-title:Drug Discovery Today
language:en
Short-container-title:Drug Discovery Today

Author:

Patel Dhrumi,Patel Bharvi,Wairkar Sarika

Publisher

Elsevier BV

Subject

Drug Discovery,Pharmacology

Reference79 articles.

1. Pharmaceutical biotechnology products approved within the European Union;Walsh;Eur J Pharm Biopharm.,2003

2. Biotechnology-based therapeutics for management of cerebral stroke;Patel;Eur J Pharmacol,2021

3. Oral delivery of systemic monoclonal antibodies, peptides and small molecules using gastric auto-injectors;Abramson;Nat Biotechnol,2022

4. Recent advancements in non-invasive formulations for protein;Bajracharya;Comput Struct Biotechnol J,2019

5. Nasal cavity, a promising transmucosal platform for drug delivery and research approaches from nasal to brain targetting;Singh;J Drug Deliv Ther,2012

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pulmonary inhalation for disease treatment: Basic research and clinical translations;Materials Today Bio;2024-04

2. Feasibility of intranasal delivery of thin-film freeze-dried monoclonal antibodies;2023-10-24

3. Liposome-Derived Nanosystems for the Treatment of Behavioral and Neurodegenerative Diseases: The Promise of Niosomes, Transfersomes, and Ethosomes for Increased Brain Drug Bioavailability;Pharmaceuticals;2023-10-08

4. Hot Spots for the Use of Intranasal Insulin: Cerebral Ischemia, Brain Injury, Diabetes Mellitus, Endocrine Disorders and Postoperative Delirium;International Journal of Molecular Sciences;2023-02-07